After first measles death in a decade, state officials remind Utahns to get the MMR vaccine
A nurse gives a measles, mumps and rubella virus vaccine at the Utah County Health Department on April 29, 2019 in Provo, Utah. (Photo by)
The Utah Department of Health and Human Services is urging Utahns to get their MMR vaccines after a Texas child died from measles.
The MMR vaccine — short for measles, mumps and rubella — has been around since the 1970s, and according to the health department, is 97% effective against measles if two doses are given.
The vaccine 'has saved millions of lives — and prevented significant suffering — around the globe,' said Leisha Nolen, a medical doctor and state epidemiologist for the Utah Department of Health and Human Services. 'The MMR vaccine is safe and effective, and Utahns are encouraged to protect their families by getting the recommended vaccine. If you have questions about vaccination, talk to a healthcare provider.'
Texas health officials say 146 people have contracted measles in the state, with 20 of them hospitalized. An unvaccinated school-aged child died, the first fatal case of measles in 10 years.
It can take one to three weeks for measles symptoms to show. It starts similar to allergies or a cold, with a cough, runny nose and fever. After several days, the patient can develop a rash which can spread to the entire body. It's particularly dangerous for children and babies, and extremely contagious — 90% of unvaccinated people who come into contact with measles will get sick, the Utah health department said.
The Utah Department of Health and Human Services is asking Utahns to check their immunization records or talk to their health care providers. To learn how to request records, check the state's website.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Georgia Dept. of Public Health confirms measles case in unvaccinated Atlanta resident
ATLANTA () — The Georgia Department of Public Health (DPH) has confirmed a secondary case of measles in an unvaccinated metro Atlanta resident. This individual is a family member of the person with measles who was confirmed in May. The DPH confirms it was acquired outside of the country. People who may have been exposed to either of these individuals have been given the MMR (measles, mumps, rubella) vaccine or antibodies to help reduce the risk of developing measles and are being monitored for symptoms. Currently, no new cases of measles have been reported outside of this family. This is the fifth reported case of measles in Georgia in 2025. In 2024, there were six reported cases of measles in the state. The Centers for Disease Control and Prevention (CDC) recommends that children receive their first dose of MMR vaccine between 12 and 15 months of age and a second dose between 4 and 6 years of age. More than 95% of the people who receive a single dose of MMR will develop immunity to all three viruses. A second dose boosts immunity, typically enhancing protection to 98%. For more information about measles, log on to or Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Intermountain Health launches cancer treatment program for patients with advanced melanoma skin cancer
SALT LAKE CITY, Utah (ABC4 Utah) – May is Melanoma Awareness Month and Intermountain Health is unveiling an exciting new treatment program for Utahns with advanced melanoma cancer – the first time local patients have been treated with this advanced technology and new therapy in the Beehive State. Thanks to this new cutting-edge personalized cancer treatment program, Utahns who have advanced melanoma cancer no longer have to leave the state to get a groundbreaking new treatment that is showing promise for patients with the deadliest type of skin cancer. Intermountain Health has launched a new program to provide tumor-infiltrating lymphocyte (TIL) therapy to treat patients with a type of skin cancer called unresectable or metastatic melanoma that cannot be removed surgically or has spread to other parts of the body. It is the first time this therapy has been used to treat patients in Utah. This novel therapy works by using special immune cells, called lymphocytes, which are taken from the tumor itself. These cells are then multiplied in a lab and put back into the patient's body to help fight the cancer. As part of the treatment process, doctors use AMTAGVI, the first and only FDA-approved prescription medication for the treatment of advanced melanoma that has not responded to standard therapies. AMTAGVI activates the patient's own immune system to target and destroy cancer cells and represents a different approach compared to other immunotherapies. Instead of broadly stimulating the immune system, it harnesses a patient's own tumor-specific T cells to directly target and destroy cancer cells. Intermountain Health cancer experts say the groundbreaking treatment marks a significant advancement in the fight against advanced melanoma, offering a new option for patients with limited treatment alternatives. 'We're excited to offer this advanced therapy and the hope it provides for improved outcomes for patients who have not responded to standard therapies,' said Tawnya Bowles, MD, a surgical oncologist at Intermountain Health. 'The promise for patients is that this treatment will work against their advanced melanoma when other treatments have failed. These patients do not have as many treatment options once their tumor has progressed on standard treatments. This therapy offers new hope for these patients.' TIL therapy has been used for decades, but AMTAGVI allows the treatment to extend beyond select treatment centers by using a protocol that lets a patient's tumor T cells grow at centralized facilities in the United States. Previously, only limited academic facilities with lab facilities could grow and expand the T cells. For Utahns, having the therapy program available locally is a major advancement. Not only does Utah have the highest incidence of melanoma in the nation, but until now, Utahns needing TIL therapy had to travel out of state for their care. 'Each year we see Utah patients who need this next step of treatment for advanced melanoma, and these patients previously had to leave the state and incur the expense of travel and the increased stress of being away from home,' said Caroline Nebhan, MD, PhD, Intermountain Health medical oncologist. 'We're thrilled to be able to offer this advanced treatment close to home with our Intermountain Health oncology team.' Patients in the new Intermountain treatment program are supported by a multi-disciplinary team of clinicians, including oncology experts and patient navigators, who work closely with patients throughout their treatment. The therapy involves surgically removing a sample of the patient's tumor, from which tumor-infiltrating lymphocytes (TILs) are extracted. These TILs, which are immune cells capable of recognizing and attacking cancer cells, are then sent to a specialized manufacturing facility where they are expanded and multiplied into billions of cells. Once the manufacturing process is complete (approximately 34 days), the patient undergoes a short course of lymphodepleting chemotherapy to prepare their body for the infusion of the expanded TILs. Following the AMTAGVI infusion, patients may receive several doses of interleukin-2 (IL-2) to further stimulate the activity and growth of the infused T cells. Patients are cared for in the hospital for a period to monitor for potential side effects. Research results of the medication were promising. Clinical trial data supporting FDA approval of AMTAGVI demonstrated promising response rates and, in many cases, prolonged outcomes in patients with advanced melanoma, suggesting the potential for long-term control of the disease. 'We're committed to providing our patients with access to the most advanced and innovative cancer treatments,' said Dr. Bowles. 'The addition of AMTAGVI to our comprehensive oncology program underscores this commitment and offers new hope for patients battling advanced melanoma.' To learn more about cancer care at Intermountain Health, go to Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Sponsored by Intermountain Health. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
3 hours ago
US measles cases nearing 30-year high
The number of measles cases in the U.S. this year has quadrupled compared to 2024 and is nearing a 30-year high. As of Friday, there have been 1,168 confirmed measles cases across 33 states nationwide, according to data from the Centers for Disease Control and Prevention. Last year, the U.S. saw just 285 measles cases, CDC data shows. The U.S. is currently on track for the highest number of measles case since 2019. The 33 states with confirmed cases include Alaska, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Montana, Nebraska, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Virginia and Washington. Among the nationally confirmed cases, the CDC says 95% are among people who are unvaccinated or whose vaccination status is unknown. Meanwhile, 2% of cases are among those who have received just one dose of the measles, mumps, rubella (MMR) vaccine and 3% of cases are among those who received the required two doses, according to the CDC. At least two school-aged children have died. Both were unvaccinated and had no known underlying conditions, according to Texas health officials said. A third measles death was recorded in New Mexico among an unvaccinated adult who tested positive after dying, according to the New Mexico Department of Health.
